Eurobio Scientific Eurobio Scientific reported revenue of 168 million euros for the 2025 fiscal year, representing a 9% increase compared to 2024. While pro forma growth (excluding acquisitions) was more modest at +2.3%, the group is reaping the rewards of its integration strategy: acquisitions in Italy and the integration of oncology product lines (EndoPredict, Prolaris) contributed nearly 10 million euros in additional revenue.
Grolleau Grolleau, a specialist in urban cabinets and critical infrastructure equipment, announced today an adjustment to its financial communication calendar.
Imerys Imerys has announced the implementation of its share buyback program authorized by the Annual General Meeting. The buybacks will involve the acquisition of a maximum of 400,000 shares, capped at 12 million euros. This price limit is lower than the maximum price authorized by the General Meeting. The program will run for a period ending no later than 27 trading days from April 10, subject to customary adjustments. LVMH The luxury goods giant will release its first-quarter revenue figures.
Semco Technologies The specialist in the design and manufacture of strategic components for semiconductor production will announce its annual results.
Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products.
The group has approximately 360 employees, three production units based in the Paris region, in Germany and in the United States, and subsidiaries in Milan in Italy, Dorking in the United Kingdom, Sissach in Switzerland, Bünde in Germany and Utrecht in the Netherlands.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
